Literature DB >> 27738753

[Predictors for need of antibradycardia and antitachycardia pacing after ICD implantation : Implications for the subcutaneous ICD].

Martin Grett1, Martin Christ2, Hans-Joachim Trappe2.   

Abstract

BACKGROUND: Little is known about the incidence and risk factors for progression to pacemaker dependency or the need for cardiac resynchronization in typical patients with an implanted defibrillator with regard to an alternative implantation of a subcutaneous ICD (S-ICD). STUDY DESIGN AND METHODS: After retrospective analysis of 291 patients with first implantation of a transvenous single chamber ICD (VVI-ICD) from 2010-2016 and excluding those with an indication for pacemaker or lack of follow-up data, 121 patients were included and investigated with regard to the following endpoints: need for pacemaker stimulation, upgrade for cardiac resynchronization (CRT), and secondary occurrence and effectiveness of antitachycardia pacing (ATP). We compared the results with those of fundamental S‑ICD studies and tried to determine risk factors on the basis of medical history and pre-implant data.
RESULTS: The study population and the rate of endpoints were significantly different to those of fundamental S‑ICD studies. Within a 2.2-year follow-up, 14.9 % of the patients developed a need for pacemaker stimulation and 0.8 % the need for cardiac resynchronization. Excluding patients who at implantation were already at high risk for pacemaker dependency, 7.4 % remained with a reached endpoint. We identified atrial fibrillation and bundle-branch-block as risk factors. All episodes of ventricular tachycardia (VT) could be terminated by ATP in 9.9 % of the patients. They more often had ischemic heart disease and a secondary prophylactic indication for an ICD.
CONCLUSION: The low rate of conversions from S‑ICD to a transvenous ICD in case of pacemaker-dependency as stated in fundamental S‑ICD studies should not be transferred to other typical collectives of ICD recipients. The latter group is at significantly higher risk for developing pacemaker-dependency.

Entities:  

Keywords:  Antitachycardia pacing; Implantable cardioverter-defibrillator; Pacemaker; Risk factors; Subcutaneous

Mesh:

Year:  2016        PMID: 27738753     DOI: 10.1007/s00399-016-0460-4

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  12 in total

1.  Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry.

Authors:  Martin C Burke; Michael R Gold; Bradley P Knight; Craig S Barr; Dominic A M J Theuns; Lucas V A Boersma; Reinoud E Knops; Raul Weiss; Angel R Leon; John M Herre; Michael Husby; Kenneth M Stein; Pier D Lambiase
Journal:  J Am Coll Cardiol       Date:  2015-04-28       Impact factor: 24.094

Review 2.  Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials.

Authors:  Johannes B van Rees; Mihály K de Bie; Joep Thijssen; C Jan Willem Borleffs; Martin J Schalij; Lieselot van Erven
Journal:  J Am Coll Cardiol       Date:  2011-08-30       Impact factor: 24.094

3.  Acute lead dislodgements and in-hospital mortality in patients enrolled in the national cardiovascular data registry implantable cardioverter defibrillator registry.

Authors:  Alan Cheng; Yongfei Wang; Jeptha P Curtis; Paul D Varosy
Journal:  J Am Coll Cardiol       Date:  2010-11-09       Impact factor: 24.094

4.  Communicating Antitachycardia Pacing-Enabled Leadless Pacemaker and Subcutaneous Implantable Defibrillator.

Authors:  Fleur V Y Tjong; Tom F Brouwer; Kirsten M Kooiman; Lonneke Smeding; Brendan Koop; Brian Soltis; Allan Shuros; Arthur A M Wilde; Martin Burke; Reinoud E Knops
Journal:  J Am Coll Cardiol       Date:  2016-03-21       Impact factor: 24.094

5.  A standardized definition of ischemic cardiomyopathy for use in clinical research.

Authors:  G Michael Felker; Linda K Shaw; Christopher M O'Connor
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

6.  Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years.

Authors:  Thomas Kleemann; Torsten Becker; Klaus Doenges; Margit Vater; Jochen Senges; Steffen Schneider; Werner Saggau; Udo Weisse; Karlheinz Seidl
Journal:  Circulation       Date:  2007-04-30       Impact factor: 29.690

7.  Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections.

Authors:  Muhammad R Sohail; Daniel Z Uslan; Akbar H Khan; Paul A Friedman; David L Hayes; Walter R Wilson; James M Steckelberg; Sarah Stoner; Larry M Baddour
Journal:  J Am Coll Cardiol       Date:  2007-04-23       Impact factor: 24.094

8.  Increased long-term mortality in patients with cardiovascular implantable electronic device infections.

Authors:  Muhammad Rizwan Sohail; Charles A Henrikson; Mary Jo Braid-Forbes; Kevin F Forbes; Daniel J Lerner
Journal:  Pacing Clin Electrophysiol       Date:  2014-09-21       Impact factor: 1.976

9.  Device-related infection among patients with pacemakers and implantable defibrillators: incidence, risk factors, and consequences.

Authors:  Pablo B Nery; Russell Fernandes; Girish M Nair; Glen L Sumner; Carlos S Ribas; Syamkumar M Divakara Menon; Xiaoyin Wang; Andrew D Krahn; Carlos A Morillo; Stuart J Connolly; Jeff S Healey
Journal:  J Cardiovasc Electrophysiol       Date:  2010-01-22

10.  Incidence of lead dislodgement, malfunction and perforation during the first year following device implantation.

Authors:  A Ghani; P P H M Delnoy; A R Ramdat Misier; J J J Smit; A Adiyaman; J P Ottervanger; A Elvan
Journal:  Neth Heart J       Date:  2014-06       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.